Lisa Sengelov

Lisa Sengelov

UNVERIFIED PROFILE

Are you Lisa Sengelov?   Register this Author

Register author
Lisa Sengelov

Lisa Sengelov

Publications by authors named "Lisa Sengelov"

Are you Lisa Sengelov?   Register this Author

34Publications

973Reads

32Profile Views

Improving information to caregivers of cancer patients: the Herlev Hospital Empowerment of Relatives through More and Earlier information Supply (HERMES) randomized controlled trial.

Support Care Cancer 2020 Feb 8;28(2):939-950. Epub 2019 Jun 8.

The Research Unit, Department of Palliative Medicine, Bispebjerg and Frederiksberg Hospital and University of Copenhagen, Bispebjerg Bakke 23, DK-2400, Copenhagen, NV, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04900-3DOI Listing
February 2020

Response to Letter to the Editor: Improving information to caregivers of cancer patients: the Herlev Hospital Empowerment of Relatives through More and Earlier information Supply (HERMES) randomized controlled trial.

Support Care Cancer 2020 Feb 13;28(2):417. Epub 2019 Nov 13.

The Research Unit, Department of Palliative Medicine, Bispebjerg and Frederiksberg Hospital and University of Copenhagen, Bispebjerg Bakke 23, DK-2400, Copenhagen, NV, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-05127-yDOI Listing
February 2020

Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer.

Scand J Urol 2017 Dec 27;51(6):457-463. Epub 2017 Jul 27.

a Department of Urology , Aarhus University Hospital , Aarhus N , Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21681805.2017.1354314DOI Listing
December 2017

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

J Clin Oncol 2017 Oct 28;35(28):3189-3197. Epub 2017 Jul 28.

Stéphane Oudard, Georges Pompidou European Hospital, Rene Descartes University; Mustapha Chadjaa; Sanofi, Paris; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Antoine Thiery-Vuillemin, Centre Hospitalier Universitaire Minjoz Besançon, Besançon, France; Lisa Sengeløv, Herlev Hospital, Herlev; Gedske Daugaard, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Steinbjørn Hansen, Odense University Hospital, Odense, Denmark; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Marie Hjälm-Eriksson, Karolinska University Hospital, Stockholm, Sweden; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Orazio Caffo, Santa Chiara Hospital, Trento, Italy; Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; John Bernard, Sanofi, Cambridge, MA; Liji Shen, Sanofi, Bridgewater, NJ; and Oliver Sartor, Tulane Cancer Center, New Orleans, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1068DOI Listing
October 2017

Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer.

Clin Genitourin Cancer 2017 04 8;15(2):e281-e287. Epub 2016 Sep 8.

Department of Oncology, Herlev University Hospital, Herlev, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.08.019DOI Listing
April 2017

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.

Cytotherapy 2017 04 15;19(4):500-513. Epub 2017 Feb 15.

Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev, Denmark; Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcyt.2017.01.007DOI Listing
April 2017

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 Jan 31;35(1):40-47. Epub 2016 Oct 31.

Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Eugene D. Kwon, Mayo Clinic, Rochester, MN; Charles G. Drake, Johns Hopkins University, Baltimore, MD; Karim Fizazi, University of Paris-Sud, Villejuif; Gwenaelle Gravis, Institut Paoli-Calmettes, Marseille, France; Christopher Logothetis, University of Texas MD Anderson Cancer Center, Houston, TX; Vinod Ganju, Monash University, Melbourne, Victoria; Siobhan S. Ng, St John of God Hospital, Subiaco, Western Australia; Francis X. Parnis, Adelaide Cancer Centre, Adelaide, South Australia, Australia; Jonathan Polikoff, Southern California Permanente Medical Group, San Marcos, CA; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada; Piotr Humanski, Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland; Josep M. Piulats, Institut Català d'Oncologia, Barcelona; Javier Puente, Hospital Clínico San Carlos, Madrid, Spain; Pablo Gonzalez Mella, Instituto Oncologico, Viña del Mar; Pablo Gonzalez Mella, Fundación Arturo Lopez Pérez, Santiago, Chile; Dirk Jaeger, University Hospital, Heidelberg, Germany; Fabio A. Franke, Hospital de Caridade de Ijuí, Ijuí, Brazil; Roman Carvajal, Hospital Regional Valentin Gomez Farias, Zapopan, Mexico; Lisa Sengeløv, Herlev Hospital, Herlev, Denmark; M. Brent McHenry, Bristol-Myers Squibb, Wallingford, CT; Arvind Varma, DOCS Inc, New York, NY; Alfonsus J. van den Eertwegh, VU University Medical Center, Amsterdam; and Winald Gerritsen, Radboud University, Nijmegen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.1584DOI Listing
January 2017

Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer.

Clin Genitourin Cancer 2016 12 24;14(6):e559-e568. Epub 2016 Mar 24.

Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.03.018DOI Listing
December 2016

Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer.

Anticancer Drugs 2016 08;27(7):695-701

Departments of aOncology bUrology, Herlev Hospital, University of Copenhagen, Herlev cDepartment of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000375DOI Listing
August 2016

Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?

Urol Oncol 2015 Nov 5;33(11):494.e15-20. Epub 2015 Aug 5.

Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439150033
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2015.06.022DOI Listing
November 2015

Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.

Cancer Immunol Immunother 2014 Nov 2;63(11):1177-87. Epub 2014 Aug 2.

Department of Hematology, Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev, Herlev Ringvej 75, 2730, Herlev, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-014-1591-2DOI Listing
November 2014

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

J Clin Oncol 2014 Jan 9;32(2):76-82. Epub 2013 Dec 9.

M. Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA; Stephane Oudard, George Pompidou European Hospital, Rene Descartes University, Paris; Nadine Houede, Institut Bergonie, Bordeaux; Tristan Maurina, CHU de Besançon, Hôpital Jean Minjoz, Besançon, France; Yen-Chuan Ou, Taichung Veterans General Hospital, Taichung, Taiwan; Lisa Sengeløv, Herlev Hospital, Herlev; Gedske Daugaard, Rigshospitalet, Copenhagen, Denmark; Fred Saad, University of Montreal, Montreal, Canada; Peter Ostler, Mount Vernon Hospital, Northwood, Middlesex; Robert Jones, Beatson West of Scotland Cancer Centre, Glasgow; Amit Bahl, Bristol Haematology and Oncology Centre, Bristol, UK; Arnulf Stenzl, Eberhard-Karls-University Medical School, Tübingen; Juergen Gschwend, Technical University of Munich, Munich, Germany; Fredrik Laestadius and Anders Ullèn, Karolinska University Hospital, Stockholm, Sweden; Daniel Castellano, I_12 Research Institute, University Hospital 12 de Octubre, Madrid, Spain; Edna Chow Maneval, Shaw-Ling Wang, and Isan Chen, Pfizer Oncology, La Jolla, CA; and Maria Jose Lechuga and Jolanda Paolini, Pfizer Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.5268DOI Listing
January 2014

[Exercise has a positive effect on health-related quality of life for people with cancer during active treatment].

Ugeskr Laeger 2013 Mar;175(13):873-6

Onkologisk Afdeling, Herlev Hospital, Herlev Ringvej 75, 2730 Herlev, Denmark.

View Article

Download full-text PDF

Source
March 2013

Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy.

Expert Opin Biol Ther 2012 Jun 16;12(6):795-804. Epub 2012 Apr 16.

Department of Oncology, University of Copenhagen, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2012.679655DOI Listing
June 2012

Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?

Acta Oncol 2008 ;47(1):110-9

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02841860701499382DOI Listing
July 2008

The immunogenicity of the hTERT540-548 peptide in cancer.

Clin Cancer Res 2008 Jan;14(1):4-7

Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-4590DOI Listing
January 2008

Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.

Eur Urol 2007 Aug 15;52(2):478-86. Epub 2007 Mar 15.

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2007.03.016DOI Listing
August 2007

[Treatment of hormonal refractory metastatic prostate cancer].

Ugeskr Laeger 2007 May;169(20):1905-7

Herlev Hospital, Onkologisk Afdeling, Herlev.

View Article

Download full-text PDF

Source
May 2007

[New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].

Ugeskr Laeger 2007 Mar;169(12):1117

Onkologisk Afdeling 54B1, Herlev Hospital, DK-2730 Herlev.

View Article

Download full-text PDF

Source
March 2007

[Chemotherapy as a supplement to radical treatment of patients with locally advanced bladder cancer].

Ugeskr Laeger 2005 Feb;167(7):749-51

Amtssygehuset i Herlev, Onkologisk Afdeling.

View Article

Download full-text PDF

Source
February 2005